PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases

Alexander Levitzki

doi:10.1016/j.cytogfr.2004.03.010

PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases

Alexander Levitzki^*

^*Corresponding author for this work

Alexander Silberman Institute of Life Sciences

Research output: Contribution to journal › Article › peer-review

82 Scopus citations

Abstract

PDGF and its receptors are involved in a variety of diseases: cancers, atherosclerosis, balloon injury induced restenosis, pulmonary fibrosis and more. In all cases enhanced signaling of the receptor is the hallmark. In some cases, like chronic myelomonocyatic leukemia (CMML), the persistent PDGFR signaling is essential for the survival of the cancer cell. These findings induced the research community as well as the pharmaceutical industry to develop agents that block PDGFR signaling. The possible utilization of PDGFR kinase inhibitors as anti-restenosis agents is likely to move ahead of the utilization of these agents to treat human malignancies.

Original language	English
Pages (from-to)	229-235
Number of pages	7
Journal	Cytokine and Growth Factor Reviews
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/j.cytogfr.2004.03.010
State	Published - Aug 2004

Keywords

Cancer
PDGF
Restenosis
Tyrphostins

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cytogfr.2004.03.010

Cite this

@article{95386a29cb874d5a816a56230a12c656,

title = "PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases",

abstract = "PDGF and its receptors are involved in a variety of diseases: cancers, atherosclerosis, balloon injury induced restenosis, pulmonary fibrosis and more. In all cases enhanced signaling of the receptor is the hallmark. In some cases, like chronic myelomonocyatic leukemia (CMML), the persistent PDGFR signaling is essential for the survival of the cancer cell. These findings induced the research community as well as the pharmaceutical industry to develop agents that block PDGFR signaling. The possible utilization of PDGFR kinase inhibitors as anti-restenosis agents is likely to move ahead of the utilization of these agents to treat human malignancies.",

keywords = "Cancer, PDGF, Restenosis, Tyrphostins",

author = "Alexander Levitzki",

year = "2004",

month = aug,

doi = "10.1016/j.cytogfr.2004.03.010",

language = "אנגלית",

volume = "15",

pages = "229--235",

journal = "Cytokine and Growth Factor Reviews",

issn = "1359-6101",

publisher = "Elsevier Ltd.",

number = "4",

}

TY - JOUR

T1 - PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases

AU - Levitzki, Alexander

PY - 2004/8

Y1 - 2004/8

N2 - PDGF and its receptors are involved in a variety of diseases: cancers, atherosclerosis, balloon injury induced restenosis, pulmonary fibrosis and more. In all cases enhanced signaling of the receptor is the hallmark. In some cases, like chronic myelomonocyatic leukemia (CMML), the persistent PDGFR signaling is essential for the survival of the cancer cell. These findings induced the research community as well as the pharmaceutical industry to develop agents that block PDGFR signaling. The possible utilization of PDGFR kinase inhibitors as anti-restenosis agents is likely to move ahead of the utilization of these agents to treat human malignancies.

AB - PDGF and its receptors are involved in a variety of diseases: cancers, atherosclerosis, balloon injury induced restenosis, pulmonary fibrosis and more. In all cases enhanced signaling of the receptor is the hallmark. In some cases, like chronic myelomonocyatic leukemia (CMML), the persistent PDGFR signaling is essential for the survival of the cancer cell. These findings induced the research community as well as the pharmaceutical industry to develop agents that block PDGFR signaling. The possible utilization of PDGFR kinase inhibitors as anti-restenosis agents is likely to move ahead of the utilization of these agents to treat human malignancies.

KW - Cancer

KW - PDGF

KW - Restenosis

KW - Tyrphostins

UR - https://www.scopus.com/pages/publications/2942630916

U2 - 10.1016/j.cytogfr.2004.03.010

DO - 10.1016/j.cytogfr.2004.03.010

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 15207814

AN - SCOPUS:2942630916

SN - 1359-6101

VL - 15

SP - 229

EP - 235

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

IS - 4

ER -

PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this